<DOC>
	<DOCNO>NCT00871364</DOCNO>
	<brief_summary>The purpose study ass single-dose relative bioavailability Actavis Group hf 50 mg venlafaxine hydrochloride tablet Wyeth Pharmaceuticals ( Effexor® ) 50 mg venlafaxine ( venlafaxine hydrochloride ) tablets fed condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : Comparative , Randomized , Single-Dose , 2-way Crossover Bioavailability Study Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets Wyeth Pharmaceuticals ( Effexor® ) 50 mg Venlafaxine Hydrochloride Tablets Healthy Adult Volunteers Fed Conditions . Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Healthy adult male female volunteer , 1855 year age . Weighing least 60 kg male 52 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) . Medically healthy subject clinically normal laboratory profile , vital sign ECGs . Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose , throughout study 6 day follow last dose use one follow acceptable birth control method : surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum ; IUD place least 3 month ; barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose , throughout study 6 day follow last dose ; surgical sterilization partner ( vasectomy 6 month minimum ) ; hormonal contraceptive least 3 month prior first dose study 6 day follow last dose . Other birth control method may deem acceptable . Postmenopausal woman amenorrhea least 2 year eligible . Gave voluntary write informed consent participate study . History presence significant cardiovascular , pulmonary , hepatic , renal , haematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction venlafaxine selective serotonin norepinephrine reuptake inhibitor ; glaucoma . Female subject pregnant lactating . Subjects test positive screening HIV , HbsAg HCV . Subjects received monoamine oxidase ( MAO ) inhibitor within 28 day prior dose . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know P450 enzyme ) within 10 day prior first dose . Subjects use drug substance know strong inducer CYP enzyme ( formerly know P450 enzyme ) within 28 day prior first dose . Subjects donate 50 499 mL blood within 30 day 499 mL within 56 day prior first dose . Subjects , completion study , would donate excess : 500 mL blood 14 day ; 1500 mL blood 180 day ; 2500 mL blood 1 year . Subjects whose PR interval &gt; 200 msec screen prior dosing . Subjects whose QTc interval &gt; 450 msec screen prior dosing . Subjects complete another clinical trial within 28 day prior first dose . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>Healthy subject</keyword>
</DOC>